Sponsor Check › Issuer
Corporation · organized in DELAWARE · formed Over five years ago · Redwood City, CA · SEC CIK 1162015
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Oct 21, 2026 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. State securities regulator actions: not yet searched. · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Coming soon.
What will be compared: what the sponsor says publicly (website, marketing materials, claimed profile) against what public records show — SEC Form D filings, Form ADV adviser registration, and state business records. Every comparison is reviewed by a person before it is published.
No comparisons published yet.
Sources to be compared: sponsor public claims · SEC Form D · SEC Form ADV (IAPD) · state business records · As of Oct 23, 2026, 9:12 PM ET.
0 of 7 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Aug 7, 2009 D/A File 021-46810 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Nov 9, 2011 D File 021-168424 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | May 15, 2026 D File 021-584215 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Oct 21, 2026 D File 021-602057 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Oct 21, 2026 D File 021-602058 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Oct 21, 2026 D File 021-602061 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Oct 21, 2026 D File 021-602063 | $0 | $0 | $0 | None listed |
As reported by the issuer on Form D (Items 12–15), latest filing per offering. "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates.
Each filing as reported by the issuer. Open a row for the full plain-English detail.
| Filing | Form D filed Oct 21, 2026 SEC file no. 021-602063 · accession 0000929638-26-003976 |
|---|---|
| Raise progress | $22,892,056 sold of Indefinite offered · Indefinite remaining |
| Filing timing | Date of first sale: Apr 29, 2010 · Form D filed: Oct 21, 2026 (6019 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 6,022 days (16.5 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 88 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Other: Series B Interests |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Nora Mende, Chief Financial Officer (Oct 21, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: Indefinite. Typical range: $2,000,000–$19,999,994. Investors: 88. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed Oct 21, 2026 SEC file no. 021-602061 · accession 0000929638-26-003975 |
|---|---|
| Raise progress | $985,000 sold of Indefinite offered · Indefinite remaining |
| Filing timing | Date of first sale: Jun 1, 2022 · Form D filed: Oct 21, 2026 (1603 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,606 days (4.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 6 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Other: Series 2022 Bridge. Includes convertible notes with 20% warrant coverage. |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Nora Mende, Chief Financial Officer (Oct 21, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: Indefinite. Typical range: $2,000,000–$19,999,994. Investors: 6. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed Oct 21, 2026 SEC file no. 021-602058 · accession 0000929638-26-003974 |
|---|---|
| Raise progress | $1,350,000 sold of Indefinite offered · Indefinite remaining |
| Filing timing | Date of first sale: Apr 20, 2023 · Form D filed: Oct 21, 2026 (1280 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,283 days (3.5 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 9 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Other: Series 2023 Bridge. Includes convertible notes with 20% warrant coverage. |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Nora Mende, Chief Financial Officer (Oct 21, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: Indefinite. Typical range: $2,000,000–$19,999,994. Investors: 9. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed Oct 21, 2026 SEC file no. 021-602057 · accession 0000929638-26-003973 |
|---|---|
| Raise progress | $4,094,500 sold of Indefinite offered · Indefinite remaining |
| Filing timing | Date of first sale: Oct 4, 2024 · Form D filed: Oct 21, 2026 (747 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 750 days (2.1 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 27 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Other: Series 2024 Bridge. Includes convertible notes with 20% warrant coverage. |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Nora Mende, Chief Financial Officer (Oct 21, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: Indefinite. Typical range: $2,000,000–$19,999,994. Investors: 27. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed May 15, 2026 SEC file no. 021-584215 · accession 0000929638-26-001870 |
|---|---|
| Raise progress | $6,093,000 sold of Indefinite offered · Indefinite remaining |
| Filing timing | Date of first sale: Jan 30, 2026 · Form D filed: May 15, 2026 (105 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 267 days (0.7 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 16 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Other: Series C Interests |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stefan Ryser, President and Chief Executive Officer (May 14, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: Indefinite. Typical range: $2,000,000–$19,999,994. Investors: 16. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Nov 9, 2011 SEC file no. 021-168424 · accession 0001162015-11-000003 |
|---|---|
| Raise progress | $235,000 sold of $300,000 offered (78%) · $65,000 remaining |
| Filing timing | Date of first sale: Oct 27, 2011 · Form D filed: Nov 9, 2011 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 5,476 days (15.0 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 8 total · issuer reported no non-accredited investors |
| Exemption claimed | 06 |
| Minimum investment accepted | $0 |
| Securities offered | Debt; Security to be acquired upon exercise; Other: Issuance of Convertible Promissory Notes and Warrants, the underlying shares of preferred stock issuable upon the conversion of the convertible promissory notes and the common stock issuable upon conversion of such preferred stock and upon the exercise of |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Glen Sato, Secretary (Nov 8, 2011) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $300,000. Typical range: $2,000,000–$19,999,994. Investors: 8. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D/A (amendment) filed Aug 7, 2009 · amends 0001162015-09-000003 ↗ SEC file no. 021-46810 · accession 0001162015-09-000004 |
|---|---|
| Raise progress | $11,715,708 sold of $13,528,314 offered (87%) · $1,812,606 remaining |
| Filing timing | Date of first sale: Jul 8, 2009 · Form D filed: Aug 7, 2009 (30 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 6,317 days (17.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 12 total · issuer reported no non-accredited investors |
| Exemption claimed | 06 |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stote Ellsworth, President (Aug 7, 2009) |
| Changes vs prior filing | total sold: $11,450,195 → $11,715,708 investors: 5 → 12 Compared with the D filed Jul 17, 2009 (EDGAR ↗). Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $13,528,314. Typical range: $2,000,000–$19,999,994. Investors: 12. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Jul 17, 2009 SEC file no. 021-46810 · accession 0001162015-09-000003 |
|---|---|
| Raise progress | $11,450,195 sold of $13,528,314 offered (85%) · $2,078,119 remaining |
| Filing timing | Date of first sale: Jul 8, 2009 · Form D filed: Jul 17, 2009 (9 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 6,317 days (17.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 5 total · issuer reported no non-accredited investors |
| Exemption claimed | 06 |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Stote Ellsworth, President (Jul 17, 2009) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $13,528,314. Typical range: $2,000,000–$19,999,994. Investors: 5. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
All Form D filings for this CIK on SEC EDGAR ↗. History: 5 new offerings in the last 12 months · most recent filing Oct 21, 2026.
| Name | Relationship | Address state | On filings | Also listed on |
|---|---|---|---|---|
| Larry Kauvar | Executive Officer Chief Science Officer | CA | May 15, 2026 → Oct 21, 2026 | — |
| Nora Mende | Executive Officer Chief Financial Officer | CA | May 15, 2026 → Oct 21, 2026 | — |
| Elisabeth Whitney | Executive Officer Chief Operating Officer | CA | May 15, 2026 | — |
| Geoff Dillon | Executive Officer Chief Business Officer | CA | May 15, 2026 | 1 other issuer |
| Stefan Ryser | Executive Officer President and Chief Executive Officer | CA | May 15, 2026 | — |
| John Friedman | Director | CA | Jul 17, 2009 → Nov 9, 2011 | 5 other issuers |
| Lawrence Kauvar | Executive Officer, Director | CA | Nov 9, 2011 | — |
| Somu Subramaniam | Director | CA | Nov 9, 2011 | 6 other issuers |
| Stote Ellsworth | Executive Officer, Director | CA | Jul 17, 2009 → Nov 9, 2011 | — |
| Thomas Lavin | Director | CA | Nov 9, 2011 | 13 other issuers |
| Gerald McMahon | Director | CA | Jul 17, 2009 → Aug 7, 2009 | 1 other issuer |
| James Broderick | Director | CA | Jul 17, 2009 → Aug 7, 2009 | 5 other issuers |
| Lawrence M. Kauvar | Executive Officer, Director | CA | Jul 17, 2009 → Aug 7, 2009 | — |
| Markus Goebel | Director | CA | Jul 17, 2009 → Aug 7, 2009 | 1 other issuer |
Executive officers, directors and promoters as self-reported by the issuer. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Other issuers listing the same people:
Shared address: this business address appears on filings for 3 other issuers. Stated as a count only — many addresses are shared office buildings or registered agents.
Not yet searched. Sources to be searched: SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected. We store official links only (company website, verified via a profile claim) and the earliest archived date of the website; never personal or family accounts.
Export this report as PDF (all source links + data timestamp; members)
No corrections have been requested for this page.
The complete public-record profile for Trellis Bioscience, Inc., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.